Term
|
Definition
| Antithrombitic, Cox inhibitor- irreversible inhibit TXA2 for PLT activation |
|
|
Term
|
Definition
| Antithrombitic, ADP inhibitor. Pro-drug, activated by CYP2C19. Irreversibly inhibits platelet aggregation, P2Y12 purinergic receptor. genetic testing, interactions are problems |
|
|
Term
|
Definition
| Antithrombitic, ADP inhibitor-Irreversibly inhibits platelet aggregation, P2Y12 purinergic receptor. |
|
|
Term
|
Definition
| Antithrombitic, ADP inhibitor- Antithrombitic, ADP inhibitor-Irreversibly inhibits platelet aggregation, P2Y12 purinergic receptor. Noncompetative, allosteric site. ↑ risk hemorrhage |
|
|
Term
|
Definition
| Antithrombitic, GP IIb/IIIa inhibitor- prevents fibrinogen from binding. prevents aggregation. Chimerized monoclonal antibody |
|
|
Term
| Eptifibatide (Integrilin) |
|
Definition
| Antithrombitic, GP IIb/IIIa inhibitor- reversibly inhibit binding of fibrinogen to GPIIb/IIIa. Less immunogenic, shorter duration Peptide fragment, resembles antibody. |
|
|
Term
|
Definition
| Antithrombitic, GP IIb/IIIa inhibitor-reversibly inhibit binding of fibrinogen to GPIIb/IIIa. Less immunogenic, shorter duration. Chemical structure mimics binding site |
|
|
Term
| Anticoagulants indication |
|
Definition
| DVT, artificial heart valves, atrial fibrillation, prophylactically after surgery |
|
|
Term
|
Definition
| prevent synthesis of functional clotting factors, eliminate activated factors IIa and Xa, directly inhibit activated factor IIa and Xa |
|
|
Term
|
Definition
| Anticoagulant, oral- rat poison. Compet. inhibit vit K, needed as cofactor for II, VII, IX, X activation. |
|
|
Term
|
Definition
| Anticoagulant- acidic glycosaminoglycan (MW 15000) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Anticoagulant, Small Heparin |
|
|
Term
|
Definition
| Anticoagulant- direct inhibitor of thrombin, most potent inhibitor, parenterally |
|
|
Term
|
Definition
| Anticoagulant- direct inhibitor of thrombin |
|
|
Term
|
Definition
| Anticoagulant- direct inhibitor of thrombin |
|
|
Term
| Dabigatran Etexilate (Pradaxa) |
|
Definition
| Anticoagulant- direct inhibitor of thrombin, Oral DTI, stroke prevention in atrial fibrillation, superior at higher doses. No antidote |
|
|
Term
|
Definition
| Anticoagulant- direct inhibitor of thrombin, oral, direct factor Xa inhibitor- prevention of DVT |
|
|
Term
|
Definition
| acts indirectly by binding to antithrombin III producing inhibition of proteolytic activity of thrombin |
|
|
Term
|
Definition
| inhibits factor Xa by ATIII |
|
|
Term
|
Definition
|
|
Term
| Streptokinase (Streptase) |
|
Definition
| Thrombolytic Agent- derived from group C Beta-hemolytic streptococci; forms complex with plasminogen |
|
|
Term
|
Definition
| Thrombolytic Agent- streptokinase activator |
|
|
Term
|
Definition
| Thrombolytic Agent- tissye plasminogen activator (tPA); fibrin selective, for massive pulmonary embolism (6hr onset), acute ischemic stroke (3hr onset) |
|
|
Term
|
Definition
| Thrombolytic Agent- tissye plasminogen activator (tPA) |
|
|
Term
|
Definition
| Thrombolytic Agent- tissye plasminogen activator (tPA) |
|
|
Term
|
Definition
| Thrombolytic Agent- tissye plasminogen activator (tPA), experimental- bat saliva |
|
|
Term
|
Definition
| dissolves clots by activating the conversion of plasminogen to plasmin- hydrolyzes fibrin |
|
|
Term
| Aminocaproic Acid (Amicar) |
|
Definition
| coagulant- plasminogen inhibitor, for hemorrhage and bleeding. AE intravascular thrombosis |
|
|
Term
|
Definition
| Coagulant- antagonizes heparin, immediate |
|
|
Term
|
Definition
| Coagulant- antidote for warfarin |
|
|
Term
|
Definition
| Anti-anemia- for hypochromic mycrocytic anemia |
|
|
Term
|
Definition
| Anti-anemia- (B12 + Folate), for megaloblastic anemia |
|
|
Term
|
Definition
| anti-anemia- for megaloblastic anemia, treat neurologic dysfunction & peripheral paresthesia |
|
|
Term
| Erythropoietin (Procrit, Epogen) |
|
Definition
| anti-anemia- glycoprotein hormone |
|
|
Term
|
Definition
| increase fetal hemoglobin; for Sickle Cell disease, Chronic myelogenous leukemia, PV |
|
|
